Shivani Kapadia

Statistics

Publications

Citations

168

H-Index

Active since

2020

Affiliations

Biogen (United States)(Current)

NeuroRx Research (Canada)

McGill University

Montreal Neurological Institute and Hospital

Shivani Kapadia is an author at Biogen (United States) specializing in multiple sclerosis, multiple sclerosis therapy, and multiple sclerosis pharmacotherapy.

ORCID

Publications per year

2020–2022

Publications

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results

Ralf Gold, Douglas L. Arnold, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2021 · 75 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +16

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

Erin E. Longbrake, Yang Mao‐Draayer, Mark Cascione et al. · Multiple Sclerosis Journal · 2020 · 43 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Sibyl Wray, Florian Then Bergh, Annette Wundes et al. · Advances in Therapy · 2022 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate

Jennifer Lyons, Richard Hughes, Kerry McCarthy et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2022 · 14 citations · Full text

Life Sciences, Immunology, Neurology +13

1–4 of 4